Efficacy of INLYTA® (axitinib) in second-line mRCC

INLYTA® demonstrated proven second-line efficacy in a robustly designed trial vs. an active comparator2

  • AXIS: a Phase III, multicentre, randomised controlled trial evaluating INLYTA® vs. sorafenib2

Adapted from Rini BI, et al. 2011
*Dose could be increased or decreased after initiation.
†Dose could be decreased after initiation.

  • All 723 patients received second-line therapy after progression in first line2
  • The largest cohort of patients received SUTENT® first line (n=389, 54%)2

INLYTA® significantly improved PFS in second line vs. sorafenib1,2

ITT group: all patients

Adapted from Rini BI, et al. 2011 and INLYTA® Summary of Product Characteristics.

Scans were assessed by blinded independent radiology review.

Summary of the safety profile

The most common (≥20%) adverse reactions observed following treatment with axitinib were diarrhoea, hypertension, fatigue, decreased appetite, nausea, dysphonia and palmar-plantar erythrodysaesthesia (hand-foot syndrome).1

References

  1. INLYTA® Summary of Product Characteristics.
  2. Rini BI, et al. Lancet 2011;378(9807):1931–1939.

PP-INL-IRL-0060 April 2020

Pfizer Home

Clinical Information